

## Special Issue

# Innovative Therapeutic Strategies, Biomarkers, and Molecular Pathways in Gastrointestinal and Hepatobiliary Cancers

### Message from the Guest Editors

Gastrointestinal and hepatobiliary cancers represent a significant global health challenge due to their high morbidity and mortality rates. This Special Issue explores the latest advancements in therapeutic strategies, emphasizing innovative approaches such as immunotherapy, targeted therapies, and combination treatments. Additionally, it highlights emerging biomarkers that facilitate early diagnosis, prognosis, and personalized medicine. The Special Issue also delves into the molecular pathways driving tumorigenesis, uncovering potential targets for drug development. By bringing together cutting-edge research and clinical insights, this collection aims to inspire breakthroughs in managing and treating these complex malignancies, fostering a deeper understanding of their underlying mechanisms and therapeutic potential.

---

### Guest Editors

Dr. Anwaar Saeed

Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA

Dr. Azhar Saeed

Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, VT 05401, USA

---

### Deadline for manuscript submissions

31 May 2026



**Current  
Oncology**

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 4.9  
Indexed in PubMed



[mdpi.com/si/231133](https://mdpi.com/si/231133)

*Current Oncology*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[currentoncology@mdpi.com](mailto:currentoncology@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[curroncol](https://mdpi.com/journal/currentoncology)





# Current Oncology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 4.9  
Indexed in PubMed



[mdpi.com/journal/  
currenocol](https://mdpi.com/journal/currenocol)



## About the Journal

### Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

---

### Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology)